Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.


TSX:TH - Post by User

Comment by SPCEO1on Jan 27, 2021 12:52pm
157 Views
Post# 32399940

RE:RE:legacy shareholder whining

RE:RE:legacy shareholder whiningI would not say that management has done a poor job of running the company. They actually have made a lot of really good decisions in the last couple of years that should have translated into better stock performance. Where they are weak is in selling their story to the market. They just had the best thing that ever happened to the company in its long history - the ability to be a phase III NASH player - and the stock is still lower than it was prior to the announcement. It is incredible that management actually pulled that off but what is the point if when they do amazing, gutsy managerial things like that if there is no ability to communicate that effectively to the market so shareholders can be rewarded for their good decisions. 

So, I have few issues with how they have managed the company internally but their management of external affairs, primarily convincing the market they have an amazing , intriguing future in two major drug markets, they have left so much on the table during one of the biggest bull markets of all time. 

They could not even arrange for a large short position on the stock which, had they done so, TH's stock price would be soaring right now (that is a joke, just in case people are not aware of what is going on in the states the last few days with heavily shorted stocks soaring). 



jeffm34 wrote: The only thing people were wrong about was managements ability to run the company successfully. If the same group is trying to take this company forward then they will likely continue making the same mistakes. 


<< Previous
Bullboard Posts
Next >>